Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and
tolerability of Idebenone in patients 18 years of age or older with non-alcoholic
steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and
fibrosis improvement will be assessed.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)